- Home
- TAK
as 05-20-2024 2:33pm EST
$.
+$.
+.%
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.3 trillion in fiscal 2023. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
| Founded: | 1781 | Country: | Japan |
| Employees: | N/A | City: | N/A |
| Market Cap: | 41.5B | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | 4.69% | Dividend Payout Frequency: | Semi-Annual |
| EPS: | 0.29 | EPS Growth: | -54.86 |
| 52 Week Low/High: | $12.77 - $16.47 | Next Earning Date: | 05-09-2024 |
| Revenue: | $28,162,232,497 | Revenue Growth: | 5.87% |
| Revenue Growth (this year): | -5.17% | Revenue Growth (next year): | 2.02% |
Share on Social Networks:
Latest Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of) News
TAK Breaking Stock News: Dive into TAK Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment
CNW Group
4 days ago
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
Pharmaceutical Technology
4 days ago
Takeda’s dengue vaccine obtains WHO prequalification
MT Newswires
5 days ago
Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification
MT Newswires
6 days ago
Update: Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
MT Newswires
6 days ago
Scilex Holding Says Federal Court Approved Settlement With Takeda Pharmaceutical in Gloperba Patent Dispute
Business Wire
6 days ago
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
Pharmaceutical Technology
7 days ago